Targeting cytochrome P450 CYP1B1 with a therapeutic cancer vaccine

References

• Farrell A. Hide and seek. Nature Milestones Cancer 1, DOI:10.1038/nrc1845 (2006) (Epub ahead of print).
   Google Scholar
• Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr. Opin. Immunol.19(2), 203–208 (2007).
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu. Rev. Immunol.22, 329–360 (2004).
   PubMed Web of Science ®Google Scholar
• Parton M, Gore M, Eisen T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J. Clin. Oncol.24(35), 5584–5592 (2006).
   Google Scholar
• Sharma P, Old LJ, Allison JP. Immunotherapeutic strategies for high-risk bladder cancer. Semin. Oncol.34(2), 165–172 (2007).
   Google Scholar
• Maloney DG. Immunotherapy for non-Hodgkin’s lymphoma: monoclonal antibodies and vaccines. J. Clin. Oncol.23(26), 6421–6428 (2005).
   PubMed Web of Science ®Google Scholar
• Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene26(25), 3637–3643 (2007).
   PubMed Web of Science ®Google Scholar
• Graziano DF, Finn OJ. Tumor antigens and tumor antigen discovery. Cancer Treat. Res.123, 89–111 (2005).
   PubMedGoogle Scholar
• Wolchok JD, Yuan J, Houghton AN et al. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol. Ther.15(11), 2044–2050 (2007).
   PubMed Web of Science ®Google Scholar
• Acres B, Limacher JM. MUC1 as a target antigen for cancer immunotherapy. Expert Rev. Vaccines4(4), 493–502 (2005).
   PubMed Web of Science ®Google Scholar
• Huang EH, Kaufman HL. CEA-based vaccines. Expert Rev. Vaccines1(1), 49–63 (2002).
   PubMedGoogle Scholar
• Sutter TR, Tang YM, Hayes CL et al. Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J. Biol. Chem.269(18), 13092–13099 (1994).
   PubMed Web of Science ®Google Scholar
• Shen Z, Wells RL, Elkind MM. Enhanced cytochrome P450 (Cyp1b1) expression, aryl hydrocarbon hydroxylase activity, cytotoxicity, and transformation of C3H 10T1/2 cells by dimethylbenz(a)anthracene in conditioned medium. Cancer Res.54(15), 4052–4056 (1994).
   PubMedGoogle Scholar
• Sissung TM, Price DK, Sparreboom A, Figg WD. Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol. Cancer Res. 4(3), 135–150 (2006).
   Google Scholar
• Alexander DL, Eltom SE, Jefcoate CR. Ah receptor regulation of CYP1B1 expression in primary mouse embryo-derived cells. Cancer Res. 57(20), 4498–4506 (1997).
   PubMed Web of Science ®Google Scholar
• Savas U, Jefcoate CR. Dual regulation of cytochrome P450EF expression via the aryl hydrocarbon receptor and protein stabilization in C3H/10T1/2 cells. Mol. Pharmacol. 45(6), 1153–1159 (1994).
   PubMed Web of Science ®Google Scholar
• Murray GI, Taylor MC, McFadyen MC et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res.57(14), 3026–3031 (1997).
   PubMed Web of Science ®Google Scholar
• McFadyen MC, Breeman S, Payne S et al. Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J. Histochem. Cytochem.47(11), 1457–1464 (1999).
   PubMed Web of Science ®Google Scholar
• Gibson P, Gill JH, Khan PA et al. Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development. Mol. Cancer Ther.2(6), 527–534 (2003).
   PubMed Web of Science ®Google Scholar
• Kumarakulasingham M, Rooney PH, Dundas SR et al. Cytochrome P450 profile of colorectal cancer: identification of markers of prognosis. Clin. Cancer Res.11(10), 3758–3765 (2005).
   PubMed Web of Science ®Google Scholar
• Downie D, McFadyen MC, Rooney PH et al. Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin. Cancer Res.11(20), 7369–7375 (2005).
   PubMed Web of Science ®Google Scholar
• McFadyen MC, Cruickshank ME, Miller ID et al. Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br. J. Cancer85(2), 242–246 (2001).
   PubMed Web of Science ®Google Scholar
• Barnett JA, Urbauer DL, Murray GI, Fuller GN, Heimberger AB. Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target. Clin. Cancer Res.13(12), 3559–3567 (2007).
   PubMed Web of Science ®Google Scholar
• Carnell DM, Smith RE, Daley FM et al. Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. Int. J. Radiat. Oncol. Biol. Phys.58(2), 500–509 (2004).
   Google Scholar
• McFadyen MC, Melvin WT, Murray GI. Cytochrome P450 CYP1B1 activity in renal cell carcinoma. Br. J. Cancer91(5), 966–971 (2004).
   PubMed Web of Science ®Google Scholar
• McFadyen MC, Murray GI. Cytochrome P450 1B1: a novel anticancer therapeutic target. Future Oncol.1(2), 259–263 (2005).
   PubMedGoogle Scholar
• Maecker B, Sherr DH, Vonderheide RH et al. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood102(9), 3287–3294 (2003).
   PubMed Web of Science ®Google Scholar
• Kim JH, Sherman ME, Curriero FC et al. Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers. Toxicol. Appl. Pharmacol.199(3), 210–219 (2004).
   PubMed Web of Science ®Google Scholar
• Spivack SD, Hurteau GJ, Reilly AA et al. CYP1B1 expression in human lung. Drug Metab. Dispos.29(6), 916–922 (2001).
   PubMed Web of Science ®Google Scholar
• Dassi C, Signorini S, Gerthoux P, Cazzaniga M, Brambilla P. Cytochrome P450 1B1 mRNA measured in blood mononuclear cells by quantitative reverse transcription-PCR. Clin. Chem.44(12), 2416–2421 (1998).
   Google Scholar
• Lin P, Hu SW, Chang TH. Correlation between gene expression of aryl hydrocarbon receptor (AhR), hydrocarbon receptor nuclear translocator (Arnt), cytochromes P4501A1 (CYP1A1) and 1B1 (CYP1B1), and inducibility of CYP1A1 and CYP1B1 in human lymphocytes. Toxicol. Sci.71(1), 20–26 (2003).
   PubMedGoogle Scholar
• Port JL, Yamaguchi K, Du B et al. Tobacco smoke induces CYP1B1 in the aerodigestive tract. Carcinogenesis25(11), 2275–2281 (2004).
   PubMedGoogle Scholar
• Willey JC, Coy EL, Frampton MW et al. Quantitative RT-PCR measurement of cytochromes p450 1A1, 1B1, and 2B7, microsomal epoxide hydrolase, and NADPH oxidoreductase expression in lung cells of smokers and nonsmokers. Am. J. Respir. Cell. Mol. Biol.17(1), 114–124 (1997).
   PubMed Web of Science ®Google Scholar
• Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv. Immunol.90, 51–81 (2006).
   PubMed Web of Science ®Google Scholar
• Li D, Wang M, Dhingra K, Hittelman WN. Aromatic DNA adducts in adjacent tissues of breast cancer patients: clues to breast cancer etiology. Cancer Res.56(2), 287–293 (1996).
   PubMed Web of Science ®Google Scholar
• Ross J, Nelson G, Kligerman A et al. Formation and persistence of novel benzo(a)pyrene adducts in rat lung, liver, and peripheral blood lymphocyte DNA. Cancer Res.50(16), 5088–5094 (1990).
   PubMed Web of Science ®Google Scholar
• van Schooten FJ, Hillebrand MJ, Scherer E, den Engelse L, Kriek E. Immunocytochemical visualization of DNA adducts in mouse tissues and human white blood cells following treatment with benzo[a]pyrene or its diol epoxide. A quantitative approach. Carcinogenesis12(3), 427–433 (1991).
   Google Scholar
• Zenzes MT, Puy LA, Bielecki R. Immunodetection of benzo[a]pyrene adducts in ovarian cells of women exposed to cigarette smoke. Mol. Hum. Reprod.4(2), 159–165 (1998).
   PubMed Web of Science ®Google Scholar
• Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA. Environmental and chemical carcinogenesis. Semin. Cancer Biol.14(6), 473–486 (2004).
   PubMed Web of Science ®Google Scholar
• Baird WM, Hooven LA, Mahadevan B. Carcinogenic polycyclic aromatic hydrocarbon-DNA adducts and mechanism of action. Environ. Mol. Mutagen.45(2–3), 106–114 (2005).
   PubMed Web of Science ®Google Scholar
• Mahadevan B, Luch A, Atkin J et al. Inhibition of human cytochrome P450 1b1 further clarifies its role in the activation of dibenzo[a,l]pyrene in cells in culture. J. Biochem. Mol. Toxicol.21(3), 101–109 (2007).
   PubMed Web of Science ®Google Scholar
• Bowes RC, 3rd, Parrish AR, Steinberg MA et al. Atypical cytochrome P450 induction profiles in glomerular mesangial cells at the mRNA and enzyme level. Evidence for CYP1A1 and CYP1B1 expression and their involvement in benzo[a]pyrene metabolism. Biochem. Pharmacol.52(4), 587–595 (1996).
   PubMed Web of Science ®Google Scholar
• Xue W, Warshawsky D. Metabolic activation of polycyclic and heterocyclic aromatic hydrocarbons and DNA damage: a review. Toxicol. Appl. Pharmacol.206(1), 73–93 (2005).
   PubMed Web of Science ®Google Scholar
• Crespi CL, Penman BW, Steimel DT et al. Development of a human lymphoblastoid cell line constitutively expressing human CYP1B1 cDNA: substrate specificity with model substrates and promutagens. Mutagenesis12(2), 83–89 (1997).
   PubMed Web of Science ®Google Scholar
• Pottenger LH, Christou M, Jefcoate CR. Purification and immunological characterization of a novel cytochrome P450 from C3H/10T1/2 cells. Arch. Biochem. Biophys.286(2), 488–497 (1991).
   PubMed Web of Science ®Google Scholar
• Pottenger LH, Jefcoate CR. Characterization of a novel cytochrome P450 from the transformable cell line, C3H/10T1/2. Carcinogenesis11(2), 321–327 (1990).
   PubMed Web of Science ®Google Scholar
• Hankinson O. The aryl hydrocarbon receptor complex. Annu. Rev. Pharmacol. Toxicol.35, 307–340 (1995).
   PubMed Web of Science ®Google Scholar
• Hushka LJ, Williams JS, Greenlee WF. Characterization of 2,3,7,8-tetrachlorodibenzofuran-dependent suppression and AH receptor pathway gene expression in the developing mouse mammary gland. Toxicol. Appl. Pharmacol.152(1), 200–210 (1998).
   PubMed Web of Science ®Google Scholar
• Rowlands JC, Gustafsson JA. Aryl hydrocarbon receptor-mediated signal transduction. Crit. Rev. Toxicol.27(2), 109–134 (1997).
   PubMed Web of Science ®Google Scholar
• Safe S, Krishnan V. Cellular and molecular biology of aryl hydrocarbon (Ah) receptor-mediated gene expression. Arch. Toxicol. Suppl.17, 99–115 (1995).
   PubMedGoogle Scholar
• Piscaglia F, Knittel T, Kobold D et al. Cellular localization of hepatic cytochrome 1B1 expression and its regulation by aromatic hydrocarbons and inflammatory cytokines. Biochem. Pharmacol.58(1), 157–165 (1999).
   PubMed Web of Science ®Google Scholar
• Umannova L, Machala M, Topinka J et al. Tumor necrosis factor-a potentiates genotoxic effects of benzo[a]pyrene in rat liver epithelial cells through upregulation of cytochrome P450 1B1 expression. Mutat. Res.640(1–2), 162–169 (2008).
   PubMed Web of Science ®Google Scholar
• Umannova L, Zatloukalova J, Machala M et al. Tumor necrosis factor-a modulates effects of aryl hydrocarbon receptor ligands on cell proliferation and expression of cytochrome P450 enzymes in rat liver “stem-like” cells. Toxicol. Sci.99(1), 79–89 (2007).
   PubMed Web of Science ®Google Scholar
• Abdel-Razzak Z, Corcos L, Fautrel A, Campion JP, Guillouzo A. Transforming growth factor-β 1 down-regulates basal and polycyclic aromatic hydrocarbon-induced cytochromes P-450 1A1 and 1A2 in adult human hepatocytes in primary culture. Mol. Pharmacol.46(6), 1100–1110 (1994).
   PubMed Web of Science ®Google Scholar
• Ke S, Rabson AB, Germino JF, Gallo MA, Tian Y. Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-a and lipopolysaccharide. J. Biol. Chem.276(43), 39638–39644 (2001).
   PubMed Web of Science ®Google Scholar
• Wen X, Walle T. Cytochrome P450 1B1, a novel chemopreventive target for benzo[a]pyrene-initiated human esophageal cancer. Cancer Lett.246(1–2), 109–114 (2007).
   PubMedGoogle Scholar
• Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science274(5286), 430–432 (1996).
   PubMed Web of Science ®Google Scholar
• Pfeifer GP, Denissenko MF, Olivier M et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene21(48), 7435–7451 (2002).
   PubMed Web of Science ®Google Scholar
• Trombino AF, Near RI, Matulka RA et al. Expression of the aryl hydrocarbon receptor/transcription factor (AhR) and AhR-regulated CYP1 gene transcripts in a rat model of mammary tumorigenesis. Breast Cancer Res. Treat.63(2), 117–131 (2000).
   PubMed Web of Science ®Google Scholar
• Andersson P, McGuire J, Rubio C et al. A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors. Proc. Natl Acad. Sci. USA99(15), 9990–9995 (2002).
   PubMed Web of Science ®Google Scholar
• Spink DC, Hayes CL, Young NR et al. The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on estrogen metabolism in MCF-7 breast cancer cells: evidence for induction of a novel 17 β-estradiol 4-hydroxylase. J. Steroid Biochem. Mol. Biol.51(5–6), 251–258 (1994).
   PubMed Web of Science ®Google Scholar
• Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? Endocr. Rev.21(1), 40–54 (2000).
   PubMed Web of Science ®Google Scholar
• Belous AR, Hachey DL, Dawling S, Roodi N, Parl FF. Cytochrome P450 1B1-mediated estrogen metabolism results in estrogen-deoxyribonucleoside adduct formation. Cancer Res.67(2), 812–817 (2007).
   PubMed Web of Science ®Google Scholar
• Buters JT, Sakai S, Richter T et al. Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas. Proc. Natl Acad. Sci. USA96(5), 1977–1982 (1999).
   PubMed Web of Science ®Google Scholar
• Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL. Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J. Pharmacol. Exp. Ther.296(2), 537–541 (2001).
   PubMed Web of Science ®Google Scholar
• McFadyen MC, McLeod HL, Jackson FC et al. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem. Pharmacol.62(2), 207–212 (2001).
   PubMed Web of Science ®Google Scholar
• Bournique B, Lemarie A. Docetaxel (taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme. Drug Metab. Dispos.30(11), 1149–1152 (2002).
   PubMed Web of Science ®Google Scholar
• Martinez VG, O’Connor R, Liang Y, Clynes M. CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance. Br. J. Cancer98(3), 564–570 (2008).
   PubMed Web of Science ®Google Scholar
• Hogquist KA, Baldwin TA, Jameson SC. Central tolerance: learning self-control in the thymus. Nat. Rev. Immunol.5(10), 772–782 (2005).
   PubMed Web of Science ®Google Scholar
• Pardoll D. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol.21, 807–839 (2003).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer8(4), 299–308 (2008).
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, June CH. A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy. Immunol. Res.27(2–3), 341–356 (2003).
   PubMed Web of Science ®Google Scholar
• Kessler JH, Melief CJ. Identification of T-cell epitopes for cancer immunotherapy. Leukemia21(9), 1859–1874 (2007).
   PubMedGoogle Scholar
• Chicz RM, Urban RG, Lane WS et al. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature358(6389), 764–768 (1992).
   PubMed Web of Science ®Google Scholar
• Singh-Jasuja H, Emmerich NP, Rammensee HG. The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol. Immunother.53(3), 187–195 (2004).
   PubMed Web of Science ®Google Scholar
• Janicki CN, Jenkinson SR, Williams NA, Morgan DJ. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration. Cancer Res.68(8), 2993–3000 (2008).
   Google Scholar
• McMahan RH, Slansky JE. Mobilizing the low-avidity T cell repertoire to kill tumors. Semin. Cancer Biol.17(4), 317–329 (2007).
   Google Scholar
• Maecker B, von Bergwelt-Baildon MS, Anderson KS et al. Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients. Clin. Exp. Immunol.141(3), 558–562 (2005).
   PubMed Web of Science ®Google Scholar
• Maecker B, von Bergwelt-Baildon MS, Sherr DH, Nadler LM, Schultze JL. Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1. Int. J. Cancer115(2), 333–336 (2005).
   PubMedGoogle Scholar
• Kvistborg P, Hadrup SR, Svane IM, Andersen MH, Straten PT. Characterization of a single peptide derived from cytochrome P450 1B1 that elicits spontaneous human leukocyte antigen (HLA)-A1 as well as HLA-B35 restricted CD8 T-cell responses in cancer patients. Hum. Immunol.69(4–5), 266–272 (2008).
   Google Scholar
• Campoli M, Ferrone S, Zea AH, Rodriguez PC, Ochoa AC. Mechanisms of tumor evasion. Cancer Treat. Res.123, 61–88 (2005).
   Google Scholar
• Knutson KL, Disis ML, Salazar LG. CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol. Immunother.56(3), 271–285 (2007).
   PubMed Web of Science ®Google Scholar
• Choo AY, Choo DK, Kim JJ, Weiner DB. DNA vaccination in immunotherapy of cancer. Cancer Treat. Res.123, 137–156 (2005).
   PubMedGoogle Scholar
• Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature356(6365), 152–154 (1992).
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science259(5102), 1745–1749 (1993).
   PubMed Web of Science ®Google Scholar
• Wang B, Ugen KE, Srikantan V et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA90(9), 4156–4160 (1993).
   PubMed Web of Science ®Google Scholar
• Wolff JA, Malone RW, Williams P et al. Direct gene transfer into mouse muscle in vivo. Science247(4949 Pt 1), 1465–1468 (1990).
   PubMed Web of Science ®Google Scholar
• Liu MA, Ulmer JB. Human clinical trials of plasmid DNA vaccines. Adv. Genet.55, 25–40 (2005).
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Wahren B, Liu MA. DNA vaccines: recent technological and clinical advances. Discov. Med.6(33), 109–112 (2006).
   PubMedGoogle Scholar
• Liniger M, Zuniga A, Naim HY. Use of viral vectors for the development of vaccines. Expert Rev. Vaccines6(2), 255–266 (2007).
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr, Chianese-Bullock KA, Bullock TN et al. Immunity to melanoma antigens: from self-tolerance to immunotherapy. Adv. Immunol.90, 243–295 (2006).
   PubMed Web of Science ®Google Scholar
• Pavlenko M, Roos AK, Lundqvist A et al. A Phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br. J. Cancer91(4), 688–694 (2004).
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Singh G, Hermanson G et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res.62(20), 5845–5852 (2002).
   PubMed Web of Science ®Google Scholar
• Rice J, Dunn S, Piper K et al. DNA fusion vaccines induce epitope-specific cytotoxic CD8+ T cells against human leukemia-associated minor histocompatibility antigens. Cancer Res.66(10), 5436–5442 (2006).
   PubMedGoogle Scholar
• Luxembourg A, Evans CF, Hannaman D. Electroporation-based DNA immunisation: translation to the clinic. Expert Opin. Biol. Ther.7(11), 1647–1664 (2007).
   PubMed Web of Science ®Google Scholar
• Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat. Rev. Cancer8(2), 108–120 (2008).
   PubMed Web of Science ®Google Scholar
• Hedley ML, Barman SP. Microparticle delivery of plasmid DNA to mammalian cells. Methods Mol. Biol.245, 265–286 (2004).
   PubMedGoogle Scholar
• O’Hagan DT, Singh M, Ulmer JB. Microparticle-based technologies for vaccines. Methods40(1), 10–19 (2006).
   PubMed Web of Science ®Google Scholar
• Hedley ML. Formulations containing poly(lactide-co-glycolide) and plasmid DNA expression vectors. Expert Opin. Biol. Ther.3(6), 903–910 (2003).
   PubMed Web of Science ®Google Scholar
• Hedley ML, Curley J, Urban R. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat. Med.4(3), 365–368 (1998).
   PubMed Web of Science ®Google Scholar
• Luby TM, Cole G, Baker L et al. Repeated immunization with plasmid DNA formulated in poly(lactide-co-glycolide) microparticles is well tolerated and stimulates durable T cell responses to the tumor-associated antigen cytochrome P450 1B1. Clin. Immunol.112(1), 45–53 (2004).
   PubMed Web of Science ®Google Scholar
• Gribben JG, Ryan DP, Boyajian R et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin. Cancer Res.11(12), 4430–4436 (2005).
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Larmonier N, Schmitt E et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol.34(2), 336–344 (2004).
   PubMed Web of Science ®Google Scholar
• Matsushita N, Pilon-Thomas SA, Martin LM, Riker AI. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J. Immunol. Methods333(1–2), 167–179 (2008).
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Puig PE et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother.56(5), 641–648 (2007).
   PubMed Web of Science ®Google Scholar
• Pages F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med.353(25), 2654–2666 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med.348(3), 203–213 (2003).
   PubMed Web of Science ®Google Scholar
• Clarke SL, Betts GJ, Plant A et al. CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE1, e129 (2006).
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med.10(9), 942–949 (2004).
   PubMed Web of Science ®Google Scholar